Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has provided an announcement.
Sumitomo Pharma Co., Ltd. has announced a strategic move involving the transfer of its Asian business to a new subsidiary, with 60% of the shares to be acquired by Marubeni Global Pharma Corporation. This decision is part of Sumitomo Pharma’s efforts to strengthen its financial foundation and achieve sustainable growth by leveraging Marubeni’s global network, with the company set to receive significant financial consideration from the transaction.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd., based in Osaka, Japan, operates in the pharmaceutical industry, focusing on the development and marketing of pharmaceutical products. The company has a significant presence in North America with key products like ORGOVYX®, MYFEMBREE®, and GEMTESA® supporting its revenue.
YTD Price Performance: 33.60%
Average Trading Volume: 662
Technical Sentiment Signal: Hold
Current Market Cap: $1.98B
For a thorough assessment of 4506 stock, go to TipRanks’ Stock Analysis page.